BCRX

Investor Moves

Name	Value	Action	Change	Price	Last Price
Steven CohenPoint72 $-9.5M ExitQ1 2026 $9M -- $9.11
Ray DalioBridgewater Associates $6M638.1k shares AddQ1 2026 $4M $9.52 $9.11
Ken GriffinCitadel Advisors $12M1.2M shares TrimQ1 2026 $229k $9.52 $9.11
Paul Tudor Jones IITudor Investment $911k95.7k shares AddQ1 2026 $18k $9.52 $9.11
Jim SimonsRenaissance Technologies $7M777k shares TrimQ1 2026 $9M $9.52 $9.11
Ken FisherFisher Asset Management $26M2.7M shares AddQ1 2026 $7M $9.52 $9.11

Congress Trades

Name	Value	Action	Amount Range	Price	Last Price
Gilbert CisnerosDemocrat $8k BuyNov 13, 2025 $1k-$15k -- $9.11

Insider Trades

Name	Value	Action	Price	Last Price
McKee Amy EDirector $100k11.2k shares SellMay 18, 2026 $8.97 $9.11
Barnes Alane PChief Legal Officer $596k62.5k shares SellMay 13, 2026 $9.54 $9.11
Heggie TheresaDirector $505k49.9k shares SellMar 20, 2026 $10.11 $9.11
Barnes Alane PChief Legal Officer $1M150k shares SellMar 16, 2026 $9.15 $9.11
Barnes Alane PChief Legal Officer $167k21.8k shares SellDec 22, 2025 $7.65 $9.11
Barnes Alane PChief Legal Officer $162k21.2k shares SellDec 15, 2025 $7.65 $9.11

News

seekingalpha.comBioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Upseekingalpha.comJun 15

globenewswire.comBioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meetingglobenewswire.comJun 12

globenewswire.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 9

globenewswire.comBioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meetingglobenewswire.comMay 27

globenewswire.comBioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026globenewswire.comMay 13

Trade BCRX

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.

CEO: Charles K. Gayer
IPO Date: Mar 4, 1994

Market Data

Open: $9.10
High: $9.54
Low: $8.98
Volume: 7.3M
Avg Volume: 4.8M
52W High: $10.32
52W Low: $6.00

Valuation

Market Cap: $1.9B
Enterprise Value: $2.6B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $327.4M
Revenue: $874.8M
Net Income: $263.9M
Cash: $89.7M
Debt: $438.9M

Events

EarningsAug 3

EPS est. 0.14